

A PROCESS FOR PRODUCING AN IRON-DEXTRAN COMPOUND, IRON-  
5 DEXTRAN COMPOUND PRODUCED ACCORDING TO SAID PROCESS,  
PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT  
OF IRON-DEFICIENCY AND USE OF SAID COMPOUND FOR THE  
PREPARATION OF A PARENTERALLY ADMINISTRABLE  
PHARMACEUTICAL COMPOSITION

10

#### A B S T R A C T

In a process for producing an iron-dextran  
compound for use in parenteral treatment of iron-  
deficiency in humans or animals a stable compound of  
15 desired relatively low molecular weight is obtained by  
using first hydrogenation and then oxidation to convert  
reducing terminal groups on the dextran molecules  
before reaction with the iron. By varying the ratio of  
hydrogenated groups to oxygenated groups the average  
20 molecular weight of the resulting iron-dextran compound  
can be varied.